Privatizing the Human Genome?

Principals behind joint-venture proposal and public effort seek to define relationships A private effort to sequence the human genome four years ahead of the Human Genome Project's 2005 goal could either compete directly with the federal project or meld seamlessly with it. Before any relationship between the two efforts becomes formalized, scientists and federal officials involved with the Human Genome Project must determine whether the private approach will work, who will own the data, how qu

Written byPaul Smaglik
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

The private effort, a joint venture between Perkin-Elmer Inc., a Norwalk, Conn., manufacturer of sequencing equipment, and J. Craig Venter , president and director of The Institute for Genomic Research (TIGR) in Rockville, Md., would be embodied by a new company formed to sequence the entire human genome by 2001, and at an estimated cost of $150 million to $300 million. Faster, more automated sequencing machines recently unveiled by Perkin-Elmer, and a different sequencing strategy espoused by Venter make that target feasible. The federally sponsored Human Genome Project, which has a total estimated budget of $3 billion, is on schedule to finish sequencing the approximately 3 billion base pairs of DNA that make up the human genome by 2005.

MIXED SIGNALS: NHGRI's Francis Collins has sent mixed signals about whether the public and private sequencing ventures can cooperate. Francis Collins , director of the National Human Genome Research Institute, cautions ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies